Equities

Avantor Inc

Avantor Inc

Actions
  • Price (EUR)19.90
  • Today's Change0.600 / 3.11%
  • Shares traded0.00
  • 1 Year change+7.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. Its segments include Laboratory Solutions and Bioscience Production. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits, and peristaltic pumps. Equipment and instrumentation include filtration systems, virus inactivation systems, analytical instruments, freezers, and biological safety cabinets. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

  • Revenue in USD (TTM)6.82bn
  • Net income in USD309.60m
  • Incorporated2016
  • Employees14.50k
  • Location
    Avantor IncBuilding One100 W Matsonford Rd Ste 200RADNOR 19087United StatesUSA
  • Phone+1 (610) 386-1700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.avantorsciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.